Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan

Kawakami, Kenji; Ohkusa, Yasushi; Kuroki, Reiki; Tanaka, Takeshi; Koyama, Kazuhiko; Harada, Yoshitaka; Iwanaga, Kensho; Yamaryo, Takeshi; Oishi, Kazunori

doi:10.1016/j.vaccine.2010.08.010

Cited by 77 publications

(40 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Primary vaccination and revaccination after 5 years with PPV23 is generally well tolerated [4,22,31,32] and provides a sustainable immune response [33]. Over the past 10 years, many studies have shown that PPV23 vaccination of at-risk adults and the elderly is a cost-effective strategy in Germany, as well as in other European and American countries [22,[34][35][36][37][38][39][40][41][42].…”

Section: Pneumococcal Polysaccharide Vaccinementioning

confidence: 99%

Cost–effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany

Jiang

Gauthier

Annemans

et al. 2012

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Section: Pneumococcal Polysaccharide Vaccinementioning

confidence: 99%

Cost–effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany

Jiang

Gauthier

Annemans

et al. 2012

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

“…The vaccination is well tolerated [4,7,18,19]. Recent economic evaluations showed that vaccinating at-risk adults and the elderly with PPV23 was a cost-effective strategy when compared with no vaccination, even when accounting for the decline in incidence of IPD in adults induced by universal childhood vaccination against pneumococcal diseases [7,[20][21][22][23][24][25][26][27][28][29].…”

mentioning

confidence: 99%

A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany

Jiang¹,

Gauthier²,

Annemans³

et al. 2012

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

“…A pneumonia diagnosis was based on clinical symptoms (cough, sputum, or fever), increased white blood cell counts or serum C-reactive protein level, and the appearance of an infiltrate on a chest radiograph at the hospitals or the clinics of the study investigators. 17 For each case, 2 controls were selected from individuals with other diseases (not pneumonia) who were matched by sex, age (in 5-year age groups), entry date (soon after a given case's entry, within about 2 months), and the visited hospital.…”

Section: Definition Of Cases and Controlsmentioning

confidence: 99%

Association between monovalent influenza A (H1N1) pdm09 vaccine and pneumonia among the elderly in the 2009–2010 season in Japan: A case-control study

Kondo¹,

Suzuki

Washio

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Abbreviations: H1N1pdm, monovalent influenza A (H1N1) pdm09; TIV, trivalent seasonal influenza vaccine; COPD, chronic obstructive pulmonary disease; ADL, activities of daily living; OR, odds ratio; CI, confidence interval.We investigated the association between monovalent influenza A (H1N1) pdm09 (H1N1pdm) vaccine and pneumonia in elderly people. Study design was a hospital-based, matched case-control study. Cases comprised patients 65 years old who had been newly diagnosed with pneumonia. For each case, 2 controls were defined as individuals with other diseases (not pneumonia) who were matched by sex, age, entry date, and the visited hospital. Study period was the interval from 1 September 2009 until 30 September 2010. Because a pandemic of influenza A (H1N1) occurred during study period, we analyzed selected subjects who had enrolled during the influenza A (H1N1) pandemic. We calculated the odds ratios (ORs) and 95% confidence intervals (CIs) for pneumonia in H1N1pdm-vaccinated subjects compared with unvaccinated subjects using a conditional logistic regression model to assess the association between H1N1pdm vaccine and pneumonia. The subjects during the period of the influenza A (H1N1) pandemic were 20 cases and 40 controls. Subjects who had received H1N1pdm vaccine showed a significantly decreased OR for pneumonia (OR D 0.10, 95% CI D 0.01-0.98) compared with unvaccinated subjects. In conclusion, H1N1pdm vaccination may have prevented pneumonia among the elderly during the 2009-2010 influenza A (H1N1) pandemic in Japan.

show abstract

Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan

Cited by 77 publications

References 34 publications

Cost–effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany

Cost–effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany

A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany

Association between monovalent influenza A (H1N1) pdm09 vaccine and pneumonia among the elderly in the 2009–2010 season in Japan: A case-control study

Contact Info

Product

Resources

About